XWAR
MRC
Market cap102mUSD
Feb 24, Last price
40.15PLN
1D
-0.37%
1Q
2.95%
Jan 2017
111.43%
IPO
174.06%
Name
Mercator Medical SA
Chart & Performance
P/E
7.19
P/S
0.68
EPS
5.58
Div Yield, %
4.01%
Shrs. gr., 5y
-2.38%
Rev. gr., 5y
0.09%
Revenues
543m
+15.70%
Net income
51m
P
CFO
-72m
L+83,686.05%
Dividend
Jul 25, 20251.61 PLN/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Mercator Medical S.A., together with its subsidiaries, manufactures and distributes disposable medical gloves, dressings, and non-woven fabric products in Europe and internationally. The company offers surgical and protective, sterile examination and protective, and household gloves; glove brackets; and single-use clothing, including caps, masks, gowns, shoe covers, surgical shirts, sleeve protectors, and patient's shirts. It also provides surgical drape sheets; sterile drapes with non-adhesive opening; surgical sets; and accessories, such as apparatus covers, limb protectors, table covers, camera covers, adhesive pockets for surgical instruments, and self-adhesive nonwoven tapes. The company markets its products under the nitrylex, opero, MERCATOR, Ansell, dermagel, santex, comfort, vinylex, iNtouch, ambulance, and ideal brands. It serves beauty; hotels, restaurants, catering, and private cleaning; agri-food; automotive; home and garden; education; and retail industries, as well as medical customers comprising healthcare units, industrial plants, retail chains, and pharmaceutical wholesalers. The company was founded in 1989 and is headquartered in Kraków, Poland. Mercator Medical S.A. operates as a subsidiary of Anabaza RAIF V.C.I.C. Ltd.
Valuation
Title PLN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||